CN116097096A - 多发性骨髓瘤中的免疫治疗靶点及其鉴定方法 - Google Patents

多发性骨髓瘤中的免疫治疗靶点及其鉴定方法 Download PDF

Info

Publication number
CN116097096A
CN116097096A CN202180024834.4A CN202180024834A CN116097096A CN 116097096 A CN116097096 A CN 116097096A CN 202180024834 A CN202180024834 A CN 202180024834A CN 116097096 A CN116097096 A CN 116097096A
Authority
CN
China
Prior art keywords
seq
cell
antibody
antigen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024834.4A
Other languages
English (en)
Chinese (zh)
Inventor
法比亚纳·佩尔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council Of Indiana University
Original Assignee
Council Of Indiana University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Of Indiana University filed Critical Council Of Indiana University
Publication of CN116097096A publication Critical patent/CN116097096A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN202180024834.4A 2020-03-27 2021-03-26 多发性骨髓瘤中的免疫治疗靶点及其鉴定方法 Pending CN116097096A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000694P 2020-03-27 2020-03-27
US63/000,694 2020-03-27
PCT/US2021/024431 WO2021195536A1 (en) 2020-03-27 2021-03-26 Immunotherapeutic targets in multiple myeloma and methods for their identification

Publications (1)

Publication Number Publication Date
CN116097096A true CN116097096A (zh) 2023-05-09

Family

ID=77890610

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024834.4A Pending CN116097096A (zh) 2020-03-27 2021-03-26 多发性骨髓瘤中的免疫治疗靶点及其鉴定方法

Country Status (8)

Country Link
US (1) US20230137672A1 (enExample)
EP (1) EP4126243A4 (enExample)
JP (1) JP2023519304A (enExample)
KR (1) KR20220160053A (enExample)
CN (1) CN116097096A (enExample)
CA (1) CA3175860A1 (enExample)
IL (1) IL296714A (enExample)
WO (1) WO2021195536A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712550A (zh) * 2023-07-11 2023-09-08 中国医学科学院血液病医院(中国医学科学院血液学研究所) 治疗高增殖活性和多药耐药的多发性骨髓瘤的组合物及其应用
CN118501473A (zh) * 2024-05-22 2024-08-16 中国人民解放军海军军医大学第二附属医院 一种IgD型多发性骨髓瘤筛查试剂盒及其筛查系统
CN120943960A (zh) * 2025-08-04 2025-11-14 郑州大学第一附属医院 靶向人cd180的特异性单克隆抗体及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
US20230365696A1 (en) * 2020-08-05 2023-11-16 Synthekine, Inc. Ifngr1 binding molecules and methods of use
CN114031690B (zh) * 2021-12-03 2022-07-15 广州百暨基因科技有限公司 靶向ccr1和nkg2d配体的嵌合抗原受体及其应用
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
CN118878662A (zh) * 2024-09-03 2024-11-01 北京大学第六医院 多肽及其应用、试剂盒及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046012A (en) * 1993-07-19 2000-04-04 Hoffmann-La Roche Inc. Antibody to IL-12 receptor
WO2001038490A2 (en) * 1999-11-29 2001-05-31 The Trustees Of Columbia University In The City Of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
US20030017463A1 (en) * 1997-09-17 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20140242072A1 (en) * 2011-09-29 2014-08-28 Bioinvent International Ab Anti-icam-1 antibodies to treat multiple-myeloma related disorders
US20170074883A1 (en) * 2015-09-14 2017-03-16 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
CN107889489A (zh) * 2015-06-25 2018-04-06 伊玛提克斯生物技术有限公司 用于骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679771B2 (en) * 2007-01-25 2014-03-25 The Regents Of The University Of California Specific N-terminal labeling of peptides and proteins in complex mixtures
WO2012022634A1 (en) * 2010-08-16 2012-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Classification, diagnosis and prognosis of multiple myeloma
CA2892490A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
CA2992797A1 (en) * 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
FR3051555B1 (fr) * 2016-05-20 2018-05-11 Horiba Abx Sas Detection de la maladie residuelle du myelome multiple
EP3344263A4 (en) * 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center CANCER ANTIGEN TARGETS AND USES THEREOF
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
US20190365806A1 (en) * 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
WO2019094360A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
AU2018368431B2 (en) * 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
CA3082611A1 (en) * 2017-11-17 2019-05-23 Memorial Sloan-Kettering Cancer Center Methods and compositions for alleviating cytokine release syndrome
EP4219559A3 (en) * 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046012A (en) * 1993-07-19 2000-04-04 Hoffmann-La Roche Inc. Antibody to IL-12 receptor
US20030017463A1 (en) * 1997-09-17 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001038490A2 (en) * 1999-11-29 2001-05-31 The Trustees Of Columbia University In The City Of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
US20140242072A1 (en) * 2011-09-29 2014-08-28 Bioinvent International Ab Anti-icam-1 antibodies to treat multiple-myeloma related disorders
CN107889489A (zh) * 2015-06-25 2018-04-06 伊玛提克斯生物技术有限公司 用于骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
US20170074883A1 (en) * 2015-09-14 2017-03-16 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANCESCO DI MEO ET AL: "Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting", 《BLOOD》, vol. 138, 23 November 2021 (2021-11-23), pages 265 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712550A (zh) * 2023-07-11 2023-09-08 中国医学科学院血液病医院(中国医学科学院血液学研究所) 治疗高增殖活性和多药耐药的多发性骨髓瘤的组合物及其应用
CN118501473A (zh) * 2024-05-22 2024-08-16 中国人民解放军海军军医大学第二附属医院 一种IgD型多发性骨髓瘤筛查试剂盒及其筛查系统
CN120943960A (zh) * 2025-08-04 2025-11-14 郑州大学第一附属医院 靶向人cd180的特异性单克隆抗体及其应用
CN120943960B (zh) * 2025-08-04 2026-05-08 郑州大学第一附属医院 靶向人cd180的特异性单克隆抗体及其应用

Also Published As

Publication number Publication date
WO2021195536A1 (en) 2021-09-30
EP4126243A4 (en) 2024-06-12
IL296714A (en) 2022-11-01
CA3175860A1 (en) 2021-09-30
EP4126243A1 (en) 2023-02-08
KR20220160053A (ko) 2022-12-05
JP2023519304A (ja) 2023-05-10
US20230137672A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP2023519304A (ja) 多発性骨髄腫における免疫療法の標的およびその同定方法
US20250243258A1 (en) Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
US20240269179A1 (en) Neoantigens as targets for immunotherapy
DK3105317T3 (en) Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
US20220265721A1 (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
US20210277120A1 (en) Compositions and methods for treatment of t cell malignancies
JP7779484B2 (ja) 抗ｂ７－ｈ３モノクローナル抗体およびその使用方法
EP4135726A1 (en) Immune cells with enhanced function
JP2019529437A (ja) 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法
JP2021072773A (ja) ｐ５３−ＭＨＣクラスＩ複合体に結合するＴ細胞受容体様抗体
US20250276064A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
JP7307424B2 (ja) 腫瘍浸潤ｔ細胞受容体レパトアの解析方法および該解析方法を用いたがん治療処置の有効性の判定方法
CN117069842B (zh) 具有特定等电点的抗人bcma纳米抗体及car-t和应用
JP2014143982A (ja) Ｔ細胞レセプターおよびその利用
EP4534554A1 (en) Mage-a1 specific tcr and use thereof
WO2023177821A2 (en) Binding domains and methods of use thereof
TW202328438A (zh) 淋巴瘤之治療
CN118344478A (zh) 抗原结合蛋白及其应用
WO2025090985A1 (en) Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof
WO2025235408A1 (en) Compositions comprising scfv sequences targeting cancer antigens and methods of use thereof
HK40123852A (en) Mage-a1 specific tcr and use thereof
HK40123134A (en) Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
Gloger Analysis of the HLA class I immunopeptidome in health and in cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination